SLC5A2 and chronic kidney disease: Based on this evidence, the Kidney Disease Global Outcome (KDIGO) guidelines for the diagnosis and treatment of CKD recommend SGLT2 inhibitors as part of the standard of care, in addition to RAS inhibition, for a substantial percentage of patients with CKD [29].